| |
| |
|
| Insider
Information: |
Edelman Joseph |
| Relationship: |
Former 10% Owner |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
42 |
|
| Direct
Shares |
630,171 |
|
|
Indirect Shares
|
332,164,708 |
|
|
| Direct
Value |
$1,337,032 |
|
|
|
Indirect Value
|
$2,799,145,704 |
|
|
| Total
Shares |
332,794,879 |
|
|
| Total
Value |
$2,800,482,736 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
79
|
21
|
|
Stock
price went up :
|
47
|
11
|
| Stock
price went down : |
32
|
10
|
| |
|
|
|
Gain/Loss Ratio : |
1.5
|
1.1
|
| Percentage
Gain/Loss : |
 9.4%
|
210.4%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Penwest Pharmaceuticals Co |
PPCO |
10% Owner |
2008-06-23 |
0 |
2008-06-23 |
6,387,546 |
Premium* |
|
|
Synageva BioPharma Corp |
GEVA |
10% Owner |
|
0 |
2011-11-02 |
0 |
Premium* |
|
|
Aegerion Pharmaceuticals, Inc. |
AEGR |
10% Owner |
2012-11-01 |
133,133 |
2012-11-29 |
2,595,293 |
Premium* |
|
|
Acelrx Pharmaceuticals Inc |
ACRX |
10% Owner |
|
0 |
2017-06-19 |
4,533,728 |
Premium* |
|
|
Amicus Therapeutics Inc |
FOLD |
10% Owner |
|
0 |
2018-10-03 |
20,724,424 |
Premium* |
|
|
VBI Vaccines Inc |
VBIV |
10% Owner |
|
0 |
2014-07-25 |
2,610,356 |
Premium* |
|
|
Aldeyra Therapeutics, Inc. |
ALDX |
10% Owner |
|
0 |
2024-04-05 |
9,275,851 |
Premium* |
|
|
Aravive Inc |
ARAV |
10% Owner |
|
0 |
2017-09-22 |
2,099,563 |
Premium* |
|
|
Kadmon Holdings, Llc |
KDMN |
10% Owner |
|
0 |
2019-11-18 |
14,636,334 |
Premium* |
|
|
Zogenix, Inc. |
ZGNX |
10% Owner |
2017-09-29 |
0 |
2018-08-10 |
4,070,357 |
Premium* |
|
|
Global Blood Therapeutics, Inc. |
GBT |
10% Owner |
2017-12-19 |
0 |
2017-12-19 |
4,889,066 |
Premium* |
|
|
Corium International, Inc. |
CORI |
10% Owner |
2018-01-16 |
0 |
2018-10-12 |
2,724,686 |
Premium* |
|
|
Albireo Pharma Inc |
ALBO |
10% Owner |
2018-01-25 |
0 |
2022-10-13 |
1,939,723 |
Premium* |
|
|
Solid Biosciences Inc |
SLDB |
Director, 10% Owner |
2018-01-30 |
0 |
2024-01-11 |
6,906,646 |
Premium* |
|
|
La Jolla Pharmaceutical Co |
LJPC |
10% Owner |
2018-02-13 |
0 |
2019-01-08 |
2,253,376 |
Premium* |
|
|
Motus Gi Holdings Inc |
MOTS |
10% Owner |
2018-02-16 |
0 |
2021-01-22 |
2,660,542 |
Premium* |
|
|
Quotient Ltd |
QTNTQ |
10% Owner |
2018-05-22 |
0 |
2022-10-31 |
7,945,211 |
Premium* |
|
|
Dova Pharmaceuticals, Inc. |
DOVA |
10% Owner |
2018-06-04 |
0 |
2019-11-12 |
0 |
Premium* |
|
|
Meiragtx Holdings Plc |
MGTX |
10% Owner |
2018-06-08 |
0 |
2023-05-05 |
11,281,103 |
Premium* |
|
|
Crinetics Pharmaceuticals, Inc. |
CRNX |
10% Owner |
2018-07-20 |
0 |
2022-04-18 |
5,321,032 |
Premium* |
|
|
Agile Therapeutics Inc |
AGRX |
10% Owner |
2018-07-26 |
0 |
2021-10-13 |
21,654,485 |
Premium* |
|
|
Verrica Pharmaceuticals Inc. |
VRCA |
10% Owner |
2018-06-19 |
0 |
2023-12-29 |
7,099,182 |
Premium* |
|
|
Athenex, Inc. |
ATNX |
10% Owner |
2019-05-06 |
0 |
2020-09-14 |
13,532,467 |
Premium* |
|
|
ADMA Biologics Inc |
ADMA |
10% Owner |
2019-05-21 |
0 |
2021-09-30 |
13,262,375 |
Premium* |
|
|
Foamix Pharmaceuticals Ltd |
FOMX |
10% Owner |
|
0 |
2019-07-29 |
11,203,881 |
Premium* |
|
|
Lyra Therapeutics, Inc. |
LYRA |
Director, 10% Owner |
2020-05-05 |
0 |
2023-05-31 |
12,757,563 |
Premium* |
|
|
VYNE Therapeutics Inc |
VYNE |
10% Owner |
2020-06-09 |
0 |
2021-08-16 |
4,935,057 |
Premium* |
|
|
Leap Therapeutics, Inc. |
LPTX |
10% Owner |
2020-06-22 |
0 |
2020-06-22 |
8,476,496 |
Premium* |
|
|
Athira Pharma, Inc. |
ATHA |
Director, 10% Owner |
|
0 |
2023-12-29 |
5,402,964 |
Premium* |
|
|
Cerevel Therapeutics Holdings, I... |
CERE |
Director |
2020-10-20 |
0 |
2024-02-20 |
10,794,876 |
Premium* |
|
|
Scynexis Inc |
SCYX |
10% Owner |
2021-01-20 |
0 |
2021-01-22 |
1,800,000 |
Premium* |
|
|
Landos Biopharma, Inc. |
LABP |
Director, 10% Owner |
|
0 |
2021-02-09 |
17,960,839 |
Premium* |
|
|
Astria Therapeutics, Inc |
ATXS |
Director |
|
0 |
2024-02-01 |
6,485,420 |
Premium* |
|
|
Prometheus Biosciences, Inc. |
RXDX |
10% Owner |
2021-03-16 |
0 |
2021-03-16 |
3,314,032 |
Premium* |
|
|
Rain Therapeutics Inc. |
RAIN |
10% Owner |
2021-04-27 |
0 |
2021-10-12 |
2,487,019 |
Premium* |
|
|
Nautilus Biotechnology, Inc |
NAUT |
10% Owner |
2021-05-24 |
497,038 |
2021-12-08 |
9,111,151 |
Premium* |
|
|
Isoplexis Corp |
ISO |
10% Owner |
2021-10-12 |
0 |
2021-10-12 |
3,554,587 |
Premium* |
|
|
Lianbio |
LIAN |
Director, 10% Owner |
|
0 |
2024-02-15 |
57,575,533 |
Premium* |
|
|
Acrivon Therapeutics, Inc. |
ACRV |
10% Owner |
|
0 |
2024-04-11 |
5,360,858 |
Premium* |
|
|
Chembio Diagnostics Inc |
CEMI |
Former 10% Owner |
2023-04-04 |
0 |
2023-04-27 |
0 |
Premium* |
|
|
Soleno Therapeutics Inc |
SLNO |
10% Owner |
|
0 |
2023-06-06 |
2,207,753 |
Premium* |
|
|
Cargo Therapeutics, Inc. |
CRGX |
Former 10% Owner |
2023-11-14 |
0 |
2023-11-14 |
333,333 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
304 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 13
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| GEVA |
Synageva BioPharma Corp |
10% Owner |
– – • |
2011-08-03 |
4 |
B |
$2.19 |
$155,100 |
I/I |
70,000 |
0 |
1.5 |
- |
|
| GEVA |
Synageva BioPharma Corp |
10% Owner |
– – • |
2011-08-04 |
4 |
B |
$2.18 |
$21,800 |
I/I |
10,000 |
0 |
1.5 |
- |
|
| GEVA |
Synageva BioPharma Corp |
10% Owner |
– – • |
2011-11-02 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,340,000) |
0 |
0 |
- |
|
| DOVA |
Dova Pharmaceuticals, Inc... |
10% Owner |
– – • |
2019-11-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(3,125,851) |
0 |
0 |
- |
|
| CEMI |
Chembio Diagnostics Inc |
Former 10% Owner |
– – – |
2023-04-27 |
4 |
D |
$0.45 |
$2,323,252 |
I/I |
(5,162,782) |
0 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
Director |
– • – |
2024-02-20 |
4 |
GD |
$0.00 |
$0 |
I/I |
170,317 |
0 |
0 |
- |
|
| LIAN |
Lianbio |
Director |
– • • |
2024-02-15 |
4 |
D |
$4.76 |
$182,955 |
I/I |
(38,436) |
17,082 |
0 |
- |
|
| LIAN |
Lianbio |
Director |
– • • |
2024-02-15 |
4 |
OE |
$2.52 |
$182,952 |
I/I |
72,600 |
36,300 |
0 |
- |
|
| SLDB |
Solid Biosciences Inc |
Director |
– • • |
2022-12-02 |
4 |
A |
$0.00 |
$15,249,996 |
I/I |
2,601,763 |
73,107 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
Director |
– • – |
2020-10-20 |
4 |
B |
$10.00 |
$1,141,000 |
I/I |
114,100 |
114,100 |
2.1 |
% |
|
| AEGR |
Aegerion Pharmaceuticals,... |
10% Owner |
– – • |
2012-10-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
133,133 |
|
- |
|
| AEGR |
Aegerion Pharmaceuticals,... |
10% Owner |
– – • |
2012-11-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
133,133 |
|
- |
|
| CERE |
Cerevel Therapeutics Hold... |
Director |
– • – |
2020-10-21 |
4 |
B |
$10.09 |
$435,838 |
I/I |
43,195 |
157,295 |
2.1 |
% |
|
| NAUT |
Nautilus Biotechnology, I... |
Director |
– • – |
2021-05-20 |
4 |
B |
$10.05 |
$1,607,246 |
I/I |
159,925 |
159,925 |
2.1 |
% |
|
| ISO |
Isoplexis Corp |
10% Owner |
– – • |
2021-10-12 |
4 |
A |
$0.00 |
$0 |
I/I |
3,245,498 |
204,949 |
0 |
- |
|
| CRNX |
Crinetics Pharmaceuticals... |
10% Owner |
– – • |
2018-07-18 |
4/A |
B |
$21.30 |
$6,552,902 |
I/I |
307,648 |
307,648 |
1.5 |
- |
|
| CRGX |
Cargo Therapeutics, Inc. |
Former 10% Owner |
– – – |
2023-11-14 |
4 |
B |
$15.00 |
$9,999,990 |
I/I |
666,666 |
333,333 |
0.01 |
- |
|
| ATHA |
Athira Pharma, Inc. |
Director |
– • • |
2020-09-17 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
411,196 |
|
- |
|
| NAUT |
Nautilus Biotechnology, I... |
Director |
– • – |
2021-06-03 |
4 |
B |
$10.05 |
$3,317,003 |
I/I |
330,050 |
489,975 |
2.1 |
% |
|
| NAUT |
Nautilus Biotechnology, I... |
Former Director |
– – – |
2021-05-24 |
4 |
B |
$10.05 |
$70,983 |
D/D |
7,063 |
497,038 |
2.44 |
% |
|
| ATXS |
Astria Therapeutics, Inc |
Director |
– • – |
2022-12-19 |
4 |
B |
$11.01 |
$9,999,998 |
I/I |
908,265 |
1,038,309 |
2.1 |
% |
|
| ALDX |
Aldeyra Therapeutics, Inc... |
10% Owner |
– – • |
2015-10-19 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,090,193 |
|
- |
|
| LYRA |
Lyra Therapeutics, Inc. |
Director |
– • • |
2020-05-05 |
4 |
A |
$0.00 |
$0 |
I/I |
2,376,082 |
1,244,066 |
0 |
- |
|
| LYRA |
Lyra Therapeutics, Inc. |
Director |
– • • |
2020-05-05 |
4 |
D |
$16.00 |
$4,149,536 |
I/I |
(259,346) |
1,288,446 |
0 |
- |
|
| LYRA |
Lyra Therapeutics, Inc. |
Director |
– • • |
2020-05-05 |
4 |
OE |
$8.63 |
$4,149,520 |
I/I |
480,825 |
1,471,620 |
0 |
- |
|
304 Records found
|
|
Page 1 of 13 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
